Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. - Wikidata - awgldk - TriplyDB

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.

http://www.wikidata.org/entity/Q45049209

about

Pharmacological treatment for antipsychotic-related constipation Tegaserod for the treatment of irritable bowel syndrome and chronic constipation Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment)Treatment for constipation: new and old pharmacological strategies A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation.Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome.Review article: the treatment of functional abdominal bloating and distension.Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument.Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation Assessment of treatment response in chronic constipation clinical trials A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation.Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.Prucalopride: the evidence for its use in the treatment of chronic constipation.Prucalopride for constipation.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Current management strategies and therapeutic targets in chronic constipation.A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation.Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.Epidemiology and management of chronic constipation in elderly patients.Effect and safety of deep needling and shallow needling for functional constipation: a multicenter, randomized controlled trial Pharmacogenomics and functional gastrointestinal disorders.Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation.Pathophysiology, diagnosis and current management of chronic constipation.The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis.Chronic constipation: advances in management.Tegaserod for treating chronic constipation in elderly patients.Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment Gene therapy of Cav1.2 channel with VIP and VIP receptor agonists and antagonists: a novel approach to designing promotility and antimotility agents Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn Novel pharmacological therapies for management of chronic constipation.Emerging drugs for chronic constipation.Systematic Review: FDA-Approved Prescription Medications for Adults With Constipation.Elobixibat for the treatment of constipation.Current and emerging pharmacotherapeutic options for irritable bowel syndrome.The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease.Pharmacological treatment for antipsychotic-related constipation.

P2860

Q24194825-888CF444-67B4-44B7-9F37-8DF051AD92F1 Q24242922-08D3D44A-74FC-4E83-815D-AD9F6127DA24 Q24607588-AC57BCD5-D1A5-4C36-A234-30FA514A0138 Q24633140-EBB0FD34-CDC9-47EE-96C9-E5A952A9AD0C Q27027346-9590D7EA-B0C2-4765-B609-A471F39EAA36 Q33436983-3F193E6F-1375-45E9-9B62-402728E1D42F Q33448962-BBE2C51D-81D0-484C-B3AD-3A0673F5793E Q33450132-AC181682-CAC0-427D-AB2C-BD78F480CC63 Q33467828-FFA35EFB-E809-4561-8CE0-1C9DB82F79ED Q33653697-3D82F692-413B-4C6A-89B9-E76ACF4C1285 Q33695487-BB3E82AA-EFC7-4FD2-AD0C-724B68D79FE6 Q33733640-0AA3C89F-1D70-4CAF-9D19-1357C4D93ACF Q33788020-04B07D39-C7E0-4456-926D-C1638C122334 Q33916182-FBBAFEEA-779E-42D9-88D5-C10FF385C621 Q33973983-59416E5B-2BBC-4172-95CB-654CDD01F1C9 Q34094831-F6D4B8A1-7256-4480-B975-C032CCA61061 Q34522966-978E5DA6-E764-4F46-AFCA-E42984C71067 Q34565704-CFF32AE0-0434-4FA6-BD76-87720017B555 Q34638259-3C556956-84D5-4DF7-9E79-582A42B2A78F Q35026383-90516050-E10E-4ADD-8AC5-A489267A341C Q35286303-7EE18738-D0AD-4482-A792-6F2D5107088A Q35694427-3F6DEE70-D34A-4991-BAB1-E5C290E52D71 Q36154036-91ED8F59-F22A-4AF3-B904-656A98D1B588 Q36192802-3A7EC6B5-7FC2-47EC-905C-D0DDEBB9D5C5 Q36321320-F903D4AC-B9AD-4636-A700-13EEB3A124C2 Q36386025-E0A5427D-4F5F-4867-90B3-CC9F1B16830A Q36407290-B73241E9-BCA4-431D-8083-6143DF1D5363 Q36426025-5909D8A2-03E8-4135-95FE-D1CA5A51005B Q36691853-BDF095B7-478F-45F1-834A-EC2E6CEF95C4 Q36709761-60A38C04-5B37-46BD-832E-ABA8AB0762CF Q36803795-B57D2788-6837-4D2E-BD42-8D54F7FCDF04 Q36807769-F4A3C31D-0DBD-4482-8CA2-75C54D0B224E Q37262609-A4F622F7-DEF5-4FF7-B4BA-D619073C6CF2 Q37394824-E01FF232-CD6E-4C0F-ADAF-B6F4DC011EDE Q37570550-45EC83A7-0887-4B12-AA9F-E07B5E9C0A85 Q37711191-38740A29-B430-4E48-B60B-EB2807E4487A Q38065210-6D7446B7-B14F-405C-B88E-3D0A469FFFD8 Q38254747-214979C4-D507-4E9B-8D69-83B05F3D8D23 Q38587559-71FC6918-785D-4E6D-A511-B1AB02158761 Q39002818-BC59FFD6-FE34-4929-A906-0A0E77555FCB

P2860

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.

http://www.wikidata.org/entity/Q45049209

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Effect of tegaserod in chronic ...... ouble-blind, controlled trial.

@en

Effect of tegaserod in chronic ...... ouble-blind, controlled trial.

@nl

type

label

Effect of tegaserod in chronic ...... ouble-blind, controlled trial.

@en

Effect of tegaserod in chronic ...... ouble-blind, controlled trial.

@nl

prefLabel

Effect of tegaserod in chronic ...... ouble-blind, controlled trial.

@en

Effect of tegaserod in chronic ...... ouble-blind, controlled trial.

@nl

P1433

Q45049209-42807EAE-9F8A-4D0F-894E-11E11089A529

P1476

Q45049209-6956BF33-00D9-47F6-A554-B1D64236AB19

P2093

Q45049209-05291DE0-A683-4383-870A-5686EC6F8B83

Q45049209-18FEE5A5-50D1-4D20-8CFC-026402925F6B

Q45049209-68F5214F-93C1-4F52-BFE2-C9D2269C3464

Q45049209-6C41CB1A-913C-42DF-9526-68DCB729D79C

Q45049209-834DD08B-17FD-4ED5-B28A-55E4C249A15C

Q45049209-A3D6AFD0-AFF3-4771-9438-9AE44AB4187C

Q45049209-B41D29FE-389F-4C74-BA06-600BCE44BCF3

Q45049209-DF4B71DA-91BC-47DE-B769-031988807B5D

Q45049209-E57EE8B9-78FD-4AA8-8B25-834E946F9C3C

P304

Q45049209-7946C188-ADCB-49A0-9DA8-0446AC0B2E88

P31

Q45049209-0C49378A-7007-4A71-9BB6-738BAC8FF7B8

P356

Q45049209-72B072E9-2E1F-4BD3-965F-C2B75C955195

P407

Q45049209-FE986334-055F-44F5-B7F3-3471125DC182

P433

Q45049209-00766D2E-CAC8-49BE-A6B6-2EF686C36F3B

P478

Q45049209-5B3E5B95-242E-4D6A-AA2D-6FEE7096841F

P577

Q45049209-51671D3A-2576-4EA4-8DF8-D4C4D628D1B7

P698

Q45049209-D018051E-231A-4C8C-AD79-207D17F2DDC2

P356

S1542-3565(04)00356-8

P1433

Clinical Gastroenterology and Hepatology

P1476

Effect of tegaserod in chronic ...... ouble-blind, controlled trial.

@en

P2093

Anthony J Lembo

http://www.w3.org/2001/XMLSchema#string

Arnold Wald

http://www.w3.org/2001/XMLSchema#string

Brigitte Nault

http://www.w3.org/2001/XMLSchema#string

Fiona Fordham

http://www.w3.org/2001/XMLSchema#string

Gervais Tougas

http://www.w3.org/2001/XMLSchema#string

James S Novick

http://www.w3.org/2001/XMLSchema#string

John F Johanson

http://www.w3.org/2001/XMLSchema#string

Mary Guella

http://www.w3.org/2001/XMLSchema#string

William D Chey

http://www.w3.org/2001/XMLSchema#string

P304

796-805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1542-3565(04)00356-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15354280

http://www.w3.org/2001/XMLSchema#string